When biology pushes back: Lessons from HBsAg-targeting therapies in hepatitis delta
Journal of Hepatology · 2026-09 · 85 (3) · 439-442
DOI: 10.1016/j.jhep.2026.06.040 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Hepatology, 2026-09. Verfasst von Thomas Berg und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. Electronic address: thomas.berg@medizin.uni-l…. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. Electronic address: thomas.berg@medizin.uni-leipzig.de.
- Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
- Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg and German Center for Infection Research (DZIF), Partner Site Heidelberg, Heidelberg, Germany.
Zitieren
APA
Berg, T., van Bömmel, F., & Urban, S. (2026). When biology pushes back: Lessons from HBsAg-targeting therapies in hepatitis delta. Journal of Hepatology, 85(3), 439-442. https://doi.org/10.1016/j.jhep.2026.06.040
Vancouver
Berg T, van Bömmel F, Urban S. When biology pushes back: Lessons from HBsAg-targeting therapies in hepatitis delta. Journal of Hepatology. 2026;85(3):439-442. doi:10.1016/j.jhep.2026.06.040
BibTeX
@article{Berg2026,
author = {Berg, Thomas and van Bömmel, Florian and Urban, Stephan},
title = {When biology pushes back: Lessons from HBsAg-targeting therapies in hepatitis delta},
journal = {Journal of Hepatology},
year = {2026},
volume = {85},
number = {3},
pages = {439--442},
doi = {10.1016/j.jhep.2026.06.040}
}
EUVIMED